Zepbound for Weight Loss
Prescribed online through TOM Weight Loss
Zepbound is the newest FDA-approved medication for chronic weight management, and it's the most effective one on the market. Built on tirzepatide, it was purpose-built for treating obesity in a way its predecessor Mounjaro wasn't. TOM Weight Loss prescribes Zepbound online to patients across Texas and Utah, with licensed physician oversight from first dose through to long-term results.
What Is Zepbound?
Zepbound is a once-weekly injectable medication containing tirzepatide, FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one related health condition. It's the on-label weight loss version of the same molecule found in Mounjaro.
Zepbound and the On-Label Weight Loss Distinction
The distinction between Zepbound and Mounjaro matters clinically. Both contain tirzepatide at identical doses, but Mounjaro is FDA-approved for type 2 diabetes while Zepbound carries a specific FDA approval for chronic weight management. For patients whose primary goal is weight loss, Zepbound is the on-label choice, and that designation has real-world implications for clinical documentation and insurance coverage pathways.
Its clinical trial results are the strongest of any currently available injectable weight loss medication. The SURMOUNT trials showed patients losing an average of 20-22% of their body weight at the highest dose. At the 15mg dose, some patients lost significantly more. That level of weight loss was, until recently, only achievable through bariatric surgery.
At TOM Weight Loss, our providers will assess whether Zepbound or compounded tirzepatide is the most appropriate and cost-effective path for you. Both contain the same active ingredient; the right choice depends on your clinical situation and budget.
Why Patients Choose Zepbound
- FDA-approved on-label for chronic weight management
- Average 20-22% body weight loss, strongest available
- Dual GIP and GLP-1 action outperforms semaglutide-only medications
- Once-weekly injection, straightforward routine
- Cleaner insurance documentation than off-label prescribing
- Available as compounded tirzepatide for significant cost savings
- Six-step titration designed to minimise side effects
- Physician-managed from first dose through maintenance
How Does Zepbound Work for Weight Loss?
Zepbound works by activating two separate hormone receptors simultaneously. This dual mechanism is what separates tirzepatide from semaglutide-based medications, and explains why Zepbound consistently outperforms them in clinical trials.
Built Specifically for Obesity
Unlike medications repurposed from diabetes treatment, Zepbound was granted its FDA approval with chronic weight management as the primary indication. The SURMOUNT trial program was designed specifically to evaluate weight loss outcomes, not blood sugar control.
GLP-1 Receptor Activation
The GLP-1 component suppresses appetite signals in the brain, slows stomach emptying, and promotes feelings of fullness after meals. This is the same mechanism used by semaglutide medications like Ozempic and Wegovy, but it's only part of how Zepbound works.
GIP Receptor Activation
The GIP component amplifies the appetite-suppressing effects of GLP-1, improves how the body processes and stores fat, and enhances insulin response. This second receptor engagement is why tirzepatide produces meaningfully greater weight loss than GLP-1 agonists alone.
Sustained Appetite Reduction
With both receptors engaged throughout the week, Zepbound produces a stronger and more consistent suppression of hunger than single-receptor medications. Patients typically report less mental preoccupation with food as treatment progresses.
Metabolic and Insulin Benefits
Tirzepatide improves insulin sensitivity and blood sugar regulation more effectively than GLP-1 agonists alone. These metabolic benefits are particularly relevant for patients with insulin resistance, pre-diabetes, or metabolic syndrome.
Clinical Trial Results
SURMOUNT-1 showed patients on 15mg tirzepatide losing an average of 22.5% of body weight over 72 weeks. At 10mg the average was 21.4%. These are the strongest weight loss outcomes recorded for any non-surgical intervention in obesity medicine.
Zepbound Dosing - What to Expect
Zepbound follows the same six-step titration as Mounjaro, reaching a maximum of 15mg weekly. The structured escalation is critical; the dose that works best for you isn't necessarily the highest one, and your TOM provider will guide every step based on your response and tolerability.
| Phase | Dose | What typically happens | Provider action |
|---|---|---|---|
| Weeks 1-4 |
2.5mg | Starting dose is intentionally low. Body adjusts to the medication with minimal appetite effect at this stage. | Baseline check-in, side effect review |
| Weeks 5-8 |
5mg | Appetite suppression becomes noticeable. Early weight loss begins. This is when most patients first experience meaningful hunger reduction. | Dose increase confirmed if tolerated |
| Weeks 9-12 |
7.5mg | Steady weight loss continues. Dual-mechanism benefits more fully engaged. Side effects typically settling by this point. | Progress check, tolerability assessment |
| Weeks 13-16 |
10mg | Significant weight loss for most patients. Clinical trial data shows strong outcomes even at this dose level without reaching maximum. | Progress assessment, dose optimisation |
| Weeks 17-20 |
12.5mg | Continued weight loss. Approaching full therapeutic range. Some patients achieve their target results here and maintain at this dose. | Review and confirm dose escalation |
| Week 21+ | 15mg (maintenance) | Maximum dose. SURMOUNT data shows average 22.5% weight loss at this level. Not every patient needs to reach 15mg to achieve excellent results. | Long-term plan review |
Zepbound Side Effects - What You Need to Know
Side effects of Zepbound are primarily gastrointestinal and most pronounced during the early weeks or when increasing the dose. The structured six-step titration schedule is specifically designed to reduce their severity.
Nausea and Vomiting
The most commonly reported side effects of Zepbound, particularly at the 5mg and 7.5mg escalation points where tirzepatide's dual-receptor activity becomes more pronounced. For most patients symptoms are mild and ease within 2-4 weeks of each new dose.
Digestive Symptoms
Diarrhea, constipation, and stomach discomfort are most common through the first three dose stages. Smaller meals, reduced fat intake, and consistent hydration all help. Your TOM provider will advise on practical adjustments specific to where you are in the Zepbound titration schedule.
Fatigue
Some patients report low energy, particularly in the early weeks of treatment. This typically improves as the body adjusts to the medication and weight loss begins.
Injection Site Reactions
Mild redness, swelling, or discomfort at the injection site is reported by some Zepbound patients, particularly when first starting treatment. Rotating injection sites each week and allowing the pen to reach room temperature before injecting significantly reduces the likelihood of localised reactions.
Less Common but Serious
Rare but documented in SURMOUNT trials: pancreatitis, gallbladder disease, low blood sugar in patients also taking insulin, and allergic reactions. Zepbound's dual-receptor mechanism means its interaction profile with insulin and other metabolic medications requires careful review. Your TOM provider will cover all relevant risks before prescribing.
Managing Side Effects
The most common reason patients stop Zepbound prematurely is unmanaged side effects. TOM Weight Loss providers guide you on dietary adjustments, hydration, and dose timing across all six titration stages, and are available when issues arise.
Zepbound vs. Other Weight Loss Medications
Zepbound and Mounjaro contain the same molecule. The meaningful comparisons are against semaglutide-based medications, where tirzepatide's dual mechanism produces consistently stronger outcomes.
| Medication | Active Ingredient | Mechanism | FDA Approval | Max Weekly Dose | Avg. Weight Loss |
|---|---|---|---|---|---|
| Zepbound | Tirzepatide | GLP-1 + GIP dual agonist | Chronic weight management | 15mg | 20-22% |
| Mounjaro | Tirzepatide | GLP-1 + GIP dual agonist | Type 2 diabetes | 15mg | 20-22% |
| Wegovy | Semaglutide | GLP-1 agonist | Chronic weight management | 2.4mg | 15-17% |
| Ozempic | Semaglutide | GLP-1 agonist | Type 2 diabetes | 2mg | 10-15% |
Zepbound is the on-label tirzepatide option for weight loss. For patients without a type 2 diabetes diagnosis, it's the clinically preferred choice over Mounjaro. Not sure which medication is right for you? Check our GLP-1 eligibility guide →
Who Qualifies for Zepbound?
Because Zepbound is FDA-approved specifically for obesity treatment, eligibility aligns directly with the clinical criteria used in its approval. Your TOM provider will confirm qualification during your consultation.
BMI and eligibility requirements
Zepbound is FDA-approved for adults who meet one of the following:
- BMI of 27+ with at least one weight-related condition (high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea)
- BMI of 30+ regardless of other conditions
- Have not achieved sufficient results through diet and exercise alone
- Want the most effective on-label weight loss medication currently available
Not sure if you qualify? Check our full GLP-1 eligibility guide →
Medical conditions that may affect eligibility
Zepbound is not suitable for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), or during pregnancy. A history of pancreatitis should also be discussed with your provider prior to starting.
Your TOM provider will review your full medical history and current medications before prescribing. This is particularly important for tirzepatide given its interaction profile with insulin and other diabetes medications.
If Zepbound isn't the right fit, your provider will discuss alternatives including Mounjaro , Wegovy , Ozempic , or oral medications.
How to Get Zepbound Online Through TOM Weight Loss
Getting started with Zepbound is fully virtual. From eligibility assessment to receiving your medication, every step happens online with a real licensed physician overseeing your care.
Free Consultation
Meet virtually with a board-certified physician who reviews your goals, health history, and confirms Zepbound eligibility under its FDA-approved criteria.
Personalised Plan
Your physician determines whether brand-name Zepbound or compounded tirzepatide is most appropriate, then builds your six-step titration schedule.
Prescription and Delivery
Your prescription is fulfilled through a licensed pharmacy and shipped refrigerated to your door, typically within 1-3 days of approval.
Ongoing Support
With six dose escalation steps and a long titration window, consistent clinical oversight makes the difference between a difficult experience and a successful one.
FDA-Approved Weight Loss, Prescribed Online
TOM Weight Loss prescribes Zepbound and compounded tirzepatide to patients across Texas and Utah through a fully online telehealth model. Zepbound's on-label status for obesity means your treatment is built on the strongest available clinical foundation, managed by licensed providers who are invested in your long-term outcomes. No office visits, no delays.
Zepbound FAQs
Common questions about Zepbound for weight loss, dosing, cost, side effects, and how it compares to other medications. Can't find your answer? Call us at 713-568-9101.
Yes, both contain tirzepatide at identical doses. The difference is FDA indication. Mounjaro is approved for type 2 diabetes; Zepbound is approved specifically for chronic weight management. For patients whose primary goal is weight loss without a type 2 diabetes diagnosis, Zepbound is the on-label, clinically preferred option.
No. Zepbound contains tirzepatide; Ozempic contains semaglutide. They work differently: Zepbound activates both GLP-1 and GIP receptors, while Ozempic activates GLP-1 alone. Zepbound produces greater average weight loss (20-22% vs. 10-15%), but they're distinct medications with different clinical profiles.
Brand-name Zepbound lists at approximately $1,060 per month without insurance. Coverage varies significantly by plan, and the on-label weight management indication gives Zepbound a slightly better insurance pathway than off-label prescribing. Compounded tirzepatide, available through TOM Weight Loss from $249/month, contains the same active ingredient at a substantially lower cost. Our team will walk you through every option.
SURMOUNT trial data shows the greatest weight loss at 10mg and 15mg weekly, with the 15mg group averaging 22.5% body weight reduction. That said, individual response varies. Some patients achieve excellent results at lower doses and never need to reach 15mg. Your TOM provider will guide dosing decisions based on your progress and tolerability at each stage.
For the right patient with appropriate clinical oversight, yes. Zepbound's SURMOUNT trial program is one of the most comprehensive clinical programs conducted for any weight loss medication, with a well-characterised safety profile. Safety comes down to proper patient selection, careful titration, and ongoing monitoring. That is what TOM Weight Loss is built to provide.
For most patients, gastrointestinal side effects peak within the first 1-2 weeks of a new dose and ease significantly by week 3-4. Moving through the six-step titration at the right pace is the single most effective way to keep side effects manageable. If side effects are disproportionate at any stage, your TOM provider can slow the titration pace.
Hair shedding is reported by some patients but is generally attributed to rapid weight loss (telogen effluvium) rather than tirzepatide itself. When significant weight is lost quickly, the body can temporarily shift the hair growth cycle. This resolves on its own within a few months for most patients. Maintaining adequate protein intake throughout treatment substantially reduces the likelihood and severity.
Yes. Zepbound should be stored in the refrigerator at 36-46°F (2-8°C). It can be kept at room temperature up to 86°F (30°C) for up to 21 days if needed, such as when travelling. Do not freeze. Full storage and handling instructions will be included with your prescription.
Yes, and for patients who have plateaued on semaglutide, transitioning to tirzepatide is often the logical next step. The dual mechanism of Zepbound frequently produces additional weight loss for patients who have stalled on GLP-1-only medications. Your TOM provider will advise on timing, appropriate starting doses, and any considerations specific to your current regimen.
Get Started With Zepbound Through TOM Weight Loss
Zepbound is the only tirzepatide medication with FDA approval built specifically around treating obesity. If you want the most effective weight loss medication currently available, prescribed on-label by a licensed physician who will manage your care from start to finish, TOM Weight Loss serves patients across Texas and Utah through a fully online, no-waiting-room model.
Prescription required. Not all patients qualify. Physician evaluation required prior to treatment. This page is for informational purposes and does not constitute medical advice. TOM Weight Loss provides telehealth weight management services across Texas and Utah. Results vary.
